Escitalopram, a new FDA-approved selective serotonin reuptake inhibitor (SSRI), significantly improves both the symptoms of generalized anxiety disorder (GAD) and quality of life of patients.
The drug is safe and well tolerated by GAD patients, researchers reported at the 12th World Congress of Psychiatry in Yokohama, Japan. Escitalopram (Lexapro) is the more potent single-isomer version of the popular anti-depressant citalopram (Celexa).
It is the first SSRI to show in pre-approval clinical trials a side-effect profile close to placebo. It received approval for treatment of major depression from the FDA on August 16, 2002.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!